Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
AstraZeneca is expanding its footprint and investment in China. The drugmaker is opening an AI Innovation Centre and a Global R&D Centre in Shanghai. The R&D site will focus on drug development for diseases common in China and other Asian countries. It will boost the firm’s R&D head count in Shanghai to about 1,000. AstraZeneca is also partnering with the investment bank China International Capital to create a $1 billion fund to invest in Chinese health-care companies and firms looking to expand in China.
This article has been sent to the following recipient: